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Abstract: Previously thought to be mainly a disorder of childhood and early adult life, coeliac
disease (CeD) is increasingly diagnosed in older adults. This may be important given the association
between CeD and osteoporosis. The primary aim of this study was to determine the seroprevalence of
undiagnosed CeD (‘at-risk serology’) in an older Australian community and relate this to a diagnosis
of osteoporosis and fractures during a follow-up period of 12 years. We included participants
from the Hunter Community Study (2004–2007) aged 55–85, who had anti-tissue transglutaminase
(tTG) titres, human leukocyte antigen (HLA) genotypes, and bone mineral density measurements
at baseline. Follow-up data included subsequent diagnosis of CeD and fractures using hospital
information. ‘At-risk’ serology was defined as both tTG and HLA positivity. Complete results were
obtained from 2122 patients. The prevalence of ‘at-risk’ serology was 5%. At baseline, 3.4% fulfilled
criteria for a diagnosis of osteoporosis. During a mean of 9.7 years of follow-up, 7.4% of the cohort
suffered at least one fracture and 0.7% were subsequently diagnosed with CeD. At-risk serology was
significantly associated with osteoporosis in a multivariate model (odds ratio 2.83, 95% confidence
interval 1.29–6.22); there was insufficient power to look at the outcome of fractures. The results
of this study demonstrate that at-risk CeD serology was significantly associated with concurrent
osteoporosis but not future fractures. Most individuals with a serological diagnosis of CeD were not
diagnosed with CeD during the follow-up period according to medical records. Coeliac disease likely
remains under-diagnosed.
Keywords: coeliac disease; osteoporosis; fractures
1. Introduction
Coeliac disease (CeD), once considered rare, is now estimated to affect 1–2% of the population
in Western countries [1,2]. It is an immune-mediated systemic condition, manifested by small
intestinal enteropathy triggered by exposure to gluten (a complex of water insoluble proteins in
wheat, rye, and barley) in the diet [1]. CeD occurs almost exclusively in those who are genetically
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predisposed with the haplotypes human leukocyte antigen (HLA)-DQA1*05-DQB1*02 (DQ2) and/or
DQA1*03-DQB1*03:02 (DQ8) [1]. Previously thought to be a childhood disorder, CeD is increasingly
diagnosed in older patients with longstanding atypical symptoms in whom the diagnosis has not
previously been pursued [3,4]. The reported biopsy proven prevalence in older populations (over
55 years) has been reported to be 0.1–2.3% [5]. This may be important given the known association
between CeD and diseases such as cancer and osteoporosis [6]. A recent study on case finding in the
general community for individuals with undiagnosed CeD showed that these subjects were more
likely to develop osteoporosis [7].
Osteoporosis is characterized by low bone mineral density (BMD) and architectural distortion
of bone tissue that leads to bone fragility and an increased risk of fractures [8]. Age and gender are
the major risk factors for the condition, which predominantly affect post-menopausal females [9].
Osteoporosis is a major public health problem, and over 4.7 million Australians over the age of 50 have
low BMD [10]. This results in fractures, with over 140,000 fractures occurring in 2012 attributed to
osteoporosis [10]. This is estimated to cost the Australian health care system over AU$3 billion per
year [10].
Osteoporosis is common in CeD, and approximately 40% of patients with newly diagnosed CeD
demonstrate a low BMD [11]. Patients with CeD are at higher risk of osteoporotic fractures [12], a risk
which persists after diagnosis [13,14] for up to 20 years [15], although the absolute increase in fracture
risk is low [12,16]. Importantly, BMD improves with a gluten free diet [17–19], although recovery
is slow, taking up to 5 years to obtain complete recovery [20], in line with the slow rate of mucosal
recovery in CeD [21]. The degree of adherence to the gluten free diet [18], and degree of mucosal
damage at follow-up [22], has been shown to correlate with the degree of BMD recovery.
The aim of this study was to determine the seroprevalence of undiagnosed CeD in an older
Australian community and relate this to a diagnosis of osteoporosis and fractures during long-term
follow-up. Secondary aims included evaluation of the association between at-risk serology at baseline,
and the presence of other autoimmune antibodies, and the rate of CeD diagnoses and death during the
follow-up period.
2. Methods
2.1. Ethics
The research was approved by the Human Research Ethics Committees of the Hunter New
England Local Health District and the University of Newcastle, Australia.
2.2. Participants
Data for this study is from the Hunter Community Study, a prospective cohort of
community-dwelling older men and women (aged 55–96 years) from Newcastle, New South Wales,
Australia. The sample characteristics and recruitment strategy has been described previously in
detail [23]. Participants were randomly selected from the electoral roll between 2004 and 2007 and
recruited using a modified Dillman strategy which included two letters of invitation followed by a
phone call to non-responders. Invitation letters were sent to 9784 individuals, of whom 7575 responded
and 3877 agreed to participate. A total of 3253 eventually participated in the study (a response rate of
44.5%). The sample has been shown previously to be comparable to the general Australian population
in terms of gender and marital status, but is slightly younger in age [23].
2.3. Baseline Measures
Several self-report questionnaires were sent to participants at baseline, covering demographics,
self-reported diseases, and prescribed and over the counter medication use. Anthropometric
measurements including standing height (measured from the floor to the vertex of the head) and
weight (measured using Tanita digital scales, Tanita, IL, USA) were taken at an initial face-to-face
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clinic visit. Bone mineral density was measured by heel ultrasound using the Sahara clinical bone
sonometer (Holologic, Bedford, MA, USA) [24]. Osteoporosis was defined as a T score of less than
or equal to −2.5 [25]. A measurement of functional capacity was performed by a ‘timed up and go
test’ [26]. Physical activity was measured using a pedometer worn for seven consecutive days during
waking hours to record step count [23]. Samples of serum and plasma were taken for serological
measures (including anti-tissue transglutaminase (anti-tTG) antibodies, anti-nuclear antibodies (ANA),
and anti-thyroid peroxidase antibodies (TPO)). Samples of serum and plasma were cryopreserved in
1 mL aliquots at −80 degrees Celsius and subsequently thawed for serological measures (including
anti-tTG antibodies, anti-nuclear antibodies (ANA), and anti-thyroid peroxidase antibodies (TPO)), as
well as DNA isolation and genotyping. Hazardous alcohol intake was defined for males and females,
respectively, as greater than five or seven standard drinks per day or more than seven or eleven drinks
on any occasion based on national guidelines [27]. Current smoking status was self-reported.
2.4. Follow-Up Measures
Non-traumatic fractures during follow-up were determined using linkage with hospital inpatient
codes arising from contact with both public and private hospitals in the state of NSW from enrolment
until 2017; data were obtained from the Centre for Health Record Linkage (CHeReL). Fractures were
excluded if they were associated with a hospital code for trauma. A subsequent diagnosis of CeD
was determined by self-report at follow-up contact made at 5 and 10 years and using hospital
inpatient codes (ICD_10). Details regarding medications targeting low bone density (including
hormone replacement therapy, selective estrogen receptor modulators, bisphosphonates, denosumab,
or teriparatide) were available via linkages with the national Pharmaceutical Benefits Scheme (PBS)
as well as through self-reporting at baseline and follow-up. Date of death was obtained through the
National Death Index.
2.5. Coeliac Serology and Genotype
Anti-tissue transglutaminase antibody levels (anti-tTG) were measured by the hospital reference
laboratory on enrolment to the study, using the AESKULISA human recombinant combined
Immunoglobulin A (IgA) and IgG anti-tTG assay (Aesku.Diagnostics, Wendelsheim, Germany).
A cut-off of ≥25 IU/mL was considered positive in line with the local reference laboratory.
HLA genotyping was performed on thawed samples using an Affymetrix Kaiser Axiom array
(ThermoFisher scientific, Waltham, MA, USA). Single nucleotide polymorphisms (SNPs) on
chromosome 6 were used to locate HLA-DQ-2.5 and 8. Three SNPs were selected for tagging the
HLA-DQ2.2 haplotype, and haplotype phasing for the three DQ2.2 tag SNPs was performed using
SHAPEIT software [28]. Those HLA-DQ2- or DQ8-positive were considered to have a permissive
genotype for CeD. “At-risk serology” for CeD was defined as a combination of anti-tTG antibodies
greater than or equal to 25 IU/mL, and a permissive genotype for CeD (positive HLA-DQ2.2,
2.5 or DQ8).
2.6. Autoimmune Serology
ANA was assessed using HEp-2 ANA slides (Bio-Rad Laboratories, Hercules, CA, USA); ANA titre
of >1/160 was defined as positive. TPO-Abs were analysed by ELISA testing (Aesku.Diagnostics,
Wendelsheim, Germany).
2.7. Statistical Analysis
Statistical analysis was performed using STATA software (StataCorp, Texas, USA). Confidence
intervals were calculated using the binomial exact method. Two models examining the association
between “at-risk serology” and osteoporosis and fractures, respectively, were constructed; adjustment
for several other potential risk factors was based on pre-designed directed acyclic graphs [29]
(see Appendixs A and B). Given that there was no difference in the mean follow-up times or mortality
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between at-risk serology groups, simple and multiple unconditional logistic regression was used.
No multivariate analysis was conducted for the outcome of fractures according to the direct acyclic
graph in order to avoid over adjustment bias for the exposure of at-risk serology (see Appendix B).
3. Results
3.1. Sample Characteristics
Of the original sample, 2121 had serum available for serology and genotype analysis and were
included in the study. The included sample was slightly older (mean age 75.9 vs. 75.3 years, p < 0.0001)
and more likely to be female than the original cohort (58.2% vs. 50.0%, p < 0.0001). The mean follow-up
time was 9.7 years (range 0.2–12.4 years).
3.2. Prevalence of ‘At-Risk’ Serology, Osteoporosis, and Fracture during Follow-Up
Of the 2121 participants included in the analysis, 59.1% (95% confidence interval (CI) 56.7–61.2)
had a permissive genotype and 7.3% (95%% CI 6.2–8.4) were determined to have a positive anti-tTG,
with 0.8% having a high titre anti-tTG (>10 time the upper limit of normal) [21]. The mean anti-tTG
was 11.4 IU/mL (range 1–313). In the entire cohort, 22.3% (95% CI 20.5–24.1) possessed at least one
allele of HLA-DQ2.2, 27.2% (95% CI 25.3–29.1) possessed at least one HLA-DQ2.5 allele, and 18.9%
(95% CI 17.3–20.6) possessed at least one HLA-DQ8 allele. ‘At-risk serology’ was present in 5.0%
(95% CI 4.1–6.0), and 2.3% of participants who had positive anti-tTG but a non-permissive genotype
for CeD (see Figure 1). Of those with a high titre anti-tTG, 88% (15/17) had a permissive HLA. There
was no difference between those with and without at-risk serology in terms of mean follow-up time
(p = 0.50).
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Figure 1. Overlap between participants with positive anti-tissue transglutaminase (anti-tTG) serology
and permissive human leukocyte antigen (HLA) genotype from the overall sample of 2121 subjects.
A diagnosis of osteoporosis was present in 3.4% (95% CI 2.6–4.2) of participants at baseline
(2.2% in males, 3.6% in emales). At least one frac ure (limb or other) occurred in 7.4% (95% CI 6.3–8.7)
of participants (n = 1883) during follow-up (see Figure 2). Of those with a baseline diagnosis of
osteoporosis, 10.2% received medicati n targeting bone density during the study period. Diagnosi
of CeD during follow-up was reported in only 0.7% (95% CI 0.4–1.1) of participants (n = 2081),
representing only 5.8% f the at-ri k serology gr up. By the end of the follow-up period, 14.1% of
the cohort had died, with n significant difference between ose with and witho t at- isk serology
(15.2% vs. 14.1%, p = 0.74).
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permissive HLA genotype, and fractures during the follow-up period from the overall sample of
1883 subjects.
3.3. Association between Coeliac Serology and Other Autoimmune Markers
Positive anti-tTG antibodies were associated with positive TPO antibodies but not ANA. In those
with positive anti-tTG antibodies, 9.5% had a positive ANA compared with 6.8% of those without
(p = 0.07), and 17.5% had a positive TPO antibodies compared with 10.0% without (p = 0.003).
3.4. Osteoporosis
In a univariate analysis, at-risk serology was ass ciated with a diagnosis of osteoporosis at
baseline (Odds Ratio [OR] 2.56, 95% CI 1.19–5.49) (see Table 1). Other factors significantly influencing
the pres nce of osteoporosi at baseline included positive anti-tTG, age, gender, body mass index
(BMI), and alcohol intak (see Tabl 1); no significant association was found for smoking or physical
activity. In the multivariate model, at-risk serology, BMI, gender, smoking status, and age, but not
alcohol intake, were all significantly associated with osteoporosis (see Table 2).
Table 1. Univariate analysis of risk factors associated with osteoporosis (OP). Risk factors are
expressed as percentages in the osteoporotic and non-osteoporotic groups unless otherwise specified.
CI—confidence interval. SD—standard deviation. BMI—body mass index.
OP—%(95% CI) No OP—%(95% CI) Odds Ratio (95% CI)
At-risk serology 11.3 (3.7–18.8) 4.7 (3.8–5.7) 2.56 (1.19–5.49)
Anti-tTG (IU/mL); mean (SD) 20.3 (50.4) 11.1 (31.0) 1.01 (1.00–1.01)
Positive anti-tTG 15.5 (6.9–24.1) 7.0 (5.9–8.1) 2.44 (1.26–4.75)
Positive HLA 63.4 ( .9–74.9) 59.0 (56.8–61. ) 1.20 ( .74–1.97)
Age (years); mean (SD) 80.2 (7.4) 75.8 (7.2) 1.08 (1.05–1.11)
BMI (kg/m2); mean (SD) 27.3 (5.3) 28.8 (4.9) 0.93 (0.88–0.98)
Gender (male) 36.6 (25.1–48.1) 50.4 (48.3–52.6) 0.57 (0.35–0.93)
Current smoker 6.1 (5.1–7.2) 9.9 (2.8–17.0) 1.67 (0.75–3.72)
Hazardous alcohol intake 1.4 (0.0–4.2) 9.7 (8.4–10.9) 0.13 (0.02–0.97)
Physical activity (step count per day); mean (SD) 6160 (5106–7216) 6700 (6530–6871) 1.00 (1.00–1.00)
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Table 2. Odds ratios from the multivariate analysis of factors associated with osteoporosis.
Odds Ratio 95% CI p Value
At-risk serology 3.09 1.32–7.23 0.009
BMI 0.94 0.89–1.00 0.04
Gender (male) 0.51 0.29–0.89 0.02
Current smoking 3.22 1.36–7.61 0.008
Hazardous alcohol intake 0.22 0.30–1.66 0.14
Age 1.08 1.04–1.12 <0.001
3.5. Fracture Risk
In those with osteoporosis, 21.2% sustained a fracture during the follow-up period, compared
with only 6.9% of the non-osteoporotic group (p < 0.001). There was no significant difference in the
rate of fractures in those with at-risk serology compared to those without (4.1% vs. 7.6%, p = 0.2)
(see Figure 2). None of the subjects with a high titre anti-tTG sustained a fracture during the follow-up
period. In the univariate analysis, fracture during follow-up was also significantly associated with age
and gender, but not BMI, smoking status, alcohol intake, physical activity, or the timed up and go test
(see Table 3). A multivariate analysis was not performed in order to avoid over adjustment bias in
accordance with the pre-constructed directed acyclic graph.
Table 3. Univariate analysis of factors associated with fractures during the follow-up period
(n = 1, 883). Risk factors are expressed as percentages in the fracture and no-fracture groups unless
otherwise specified.
Fracture—% (95% CI) No Fracture—% (95% CI) Odds Ratio (95% CI)
Osteoporosis (baseline) 10.0 (5.0–15.0) 3.0 (2.2–3.8) 3.6 (1.9–6.7)
At-risk serology 2.9 (0.1–5.7) 5.3 (4.3–6.4) 0.52 (0.19–1.44)
Anti-tTG (IU/mL); mean (SD) 8.0 (5.1–10.8) 11.6 (10.1–13.2) 0.99 (0.98–1.00)
Positive anti-tTG 5.0 (1.3–8.7) 7.5 (6.3–8.8) 0.64 (0.30–1.41)
Positive HLA 6.4 (5.6–7.2) 5.9 (5.7–6.2) 1.2 (0.9–1.8)
Positive tTG with non-permissive HLA 2.3 (−0.3–4.6) 2.2 (1.5–2.9) 0.98 (0.30–3.22)
Age (years); mean (SD) 80.4 (79.0–81.7) 76.0 (75.6–76.3) 1.08 (1.06–1.11)
BMI (kg/m2); mean (SD) 28.9 (27.9–29.9) 28.9 (28.6–29.1) 1.00 (0.97–1.04)
Gender (male) 33.6 (25.7–41.5) 51.7 (49.3–54.0) 0.47 (0.33–0.68)
Current smoker 5.0 (1.3–8.7) 6.0 (4.9–7.1) 0.83 (0.38–1.82)
Hazardous alcohol intake 7.1 (2.8–11.5) 9.8 (8.4–11.2) 0.71 (0.36–1.37)
Physical activity (step count per day); mean 6282 (5554–7101) 6615 (6433–6797) 1.00 (1.00–1.00)
Timed up and go test (seconds) 10.7 (10.0–11.4) 9.9 (8.8–11.1) 1.00 (1.00–1.01)
4. Discussion
We report a high prevalence of at-risk serology, with 5% of the sample having an elevated anti-tTG
and a permissive genotype for CeD. However, 2.3% of the cohort returned a positive anti-tTG in the
absence of permissive genotype, likely representing false positives. It follows that a proportion of
the ‘at-risk’ group would not have CeD if gastroscopy and duodenal biopsy were undertaken. This is
consistent with a previous seroprevalence study from Australia by Anderson et al. [30], which reported
anti-tTG IgA antibody positivity in 5.7% of a general population cohort (median age 54–56 years in
two combined cohorts), in whom approximately one-third had a non-permissive genotype for CeD.
The eventual prevalence of CeD in this cohort, estimated based on biopsy or extended serological
screening, was 1.2–1.9%. They suggested that in those who screen positive on anti-tTG, testing for
HLA-DQ status would reduce unnecessary gastroscopies due to false positive serology by 40% [30].
Our findings of similarly high rates of positive anti-tTG in the presence of non-permissive genotype
support these observations.
Second generation anti-tTG assays, employing human purified or human recombinant anti-tTG
antigen (as used in our assay) have been shown to be highly sensitive and specific, with a positive
predictive value of 85–100% [31,32]. These studies, however, are generally performed in cohorts
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with a high prevalence of disease and therefore high pre-test probabilities for an eventual diagnosis,
and their performance in general population screening cohorts is likely to be lower [33]. Furthermore,
there are no studies, to our knowledge, examining the performance of these assays specifically in older
adults. Reports regarding false positive anti-tTG results are not uncommon, and high rates of false
positivity have been demonstrated in cohorts with other autoimmune diseases [34], inflammatory
bowel disease [35,36], congestive heart failure [37], and liver disease [38,39]. The link between
osteoporosis and chronic diseases such as these is well established [40], and may partially explain
the link between positive serology and osteoporosis, although we did not evaluate these conditions
in this study. High rates of autoimmune markers have been previously reported in our own cohort,
with 8% of the overall cohort testing positive for anti-TPO antibodies, and 27% testing positive for ANA
antibodies [41]. We observed higher rates of both ANA and TPO antibodies in those testing positive
for anti-tTG antibodies, although this result was only statistically significant for TPO antibodies and
approached significance (p = 0.07) for ANA. There are two potential explanations for this. The first is
that autoantibody findings are common in an ageing population, explaining the association between
these autoantibodies and a positive anti-tTG. The second, specifically in regard to thyroid specific
antibodies, is that CeD and autoimmune thyroid disease are associated [21,42], and the association
between these antibodies in our cohort represents an underlying association between undiagnosed
CeD and thyroid disease. Although some have called for serological diagnosis of CeD in adults
(without biopsy) [43], the observations reported here do not support this diagnostic approach in
older adults.
Whilst the worldwide prevalence of CeD is thought to be 1–2% [42], this may be higher in older
cohorts. A study by Vilppula et al. [6] of 2815 subjects over 55 years of age in Finland screened
participants for CeD using serology, with positive cases going on to have duodenal biopsy to confirm
the presence of CeD. They reported positive serology in 2.5% of the group, but only 2.1% were
subsequently biopsy proven. A subset of this group was rescreened again 3 years later, of whom six
had undergone seroconversion and five had developed biopsy proven CeD, representing an increase
in seroprevalence to 2.7% and a biopsy proven prevalence to 2.3%, and suggesting an incidence rate of
0.08% per year [6].
The link between biopsy proven CeD and osteoporosis is well established, with a prevalence
of around 40% [11]. We report an association between positive serology (in the absence of biopsy
confirmation) and osteoporosis. This is consistent with previous literature which has also associated
anti-tTG seropositivity with low bone mineral density. Duerksen et al. [44] retrospectively evaluated
376 women who had both coeliac serology (anti-endomysial /tTG Ab) and bone mineral density tested
(with bone mineral density preceding coeliac serology by at least 6 months). They reported higher
rates of osteoporosis (68% vs. 45%, p < 0.05) in seropositive compared with seronegative women,
respectively. This has also been confirmed in a study from the USA in which undiagnosed CeD patients
were more likely to develop osteoporosis and autoimmune conditions, heralding CeD in older life
rather than classic malabsorption [7].
A gluten free diet improves bone mineral density in CeD patients, with complete resolution of
low BMD in younger patients after two years treatment with a gluten free diet [45]. The addition of
bisphosphonates, traditionally the first line pharmacologic therapy for osteoporosis, has been shown
to be no more effective than a gluten free diet alone [46]. Other traditional adjunctive therapies,
such as exercise, have also been shown to contribute little to BMD recovery in the context of gluten
withdrawal [19]. This suggests that the pathogenesis of osteoporosis is different in CeD, and related
to malabsorption of nutrients involved in bone mineralisation such as vitamin D [47], rather than
hormonal regulation of bone architecture.
If indeed a relationship exists between CeD serology and osteoporosis, this may be mediated by a
combination of factors, including a subset with undiagnosed CeD who develop osteoporosis secondary
to enteropathy, malabsorption, and low-grade inflammation, as well as a relationship between chronic
diseases that increase the likelihood of having both osteoporosis and false positive CeD serology.
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There was no significant association between at-risk serology and fractures sustained during the
follow-up period (20,181 person years). However, with only four participants with at-risk serology
sustaining a fracture during follow-up, it is likely that the analysis was underpowered to evaluate
this outcome. A systematic review by Olmos et al. [12] of case-control and cross sectional studies
examining fracture risk in CeD, which included eight studies of 20,995 CeD patients and 96,777 controls,
reported a fracture risk of 8.7% in CeD and 6.15% in controls (OR 1.43, 95% CI 1.15–1.78). A more recent
meta-analysis by Heikkila et al. [48] limited to six prospective studies reported a slightly increased
risk of bone fractures (random effects estimate: 1.30, 95% CI 1.14–1.50). Few prospective studies
have examined the association between undiagnosed CeD and osteoporosis or fracture risk [48].
Agardh et al. [49] reported a study of 6480 women aged 50–64 years old (mean age 56 years) in
whom both BMD (by wrist dual X-ray absorptiometry) and anti-tTG measurements were taken;
they found that those with elevated tTG (≥17 IU/mL), representing approximately 0.9% of the sample,
were significantly more likely to have osteoporosis (13.4% vs. 6.5%, p = 0.008) and fracture risk (32% vs.
19%, p = 0.009).
This study has a number of strengths, including the relatively unique demographic profile of
the cohort, the availability of both serological measures and bone mineral density measurements
at baseline, as well as long-term follow-up allowing us to estimate fractures over a 12-year period.
One significant limitation of this study is the lack of confirmatory biopsy for the diagnosis of CeD.
We defined a subsequent diagnosis of CeD based on hospital coding information and self-report
at follow-up as available tools of diagnosis. As mentioned, the high rate of false positivity of the
anti-tTG assay means that a significant proportion of the ‘at-risk’ group are likely not to have CeD
on confirmatory biopsy. Another limitation of this study is the measurement of bone mineral density,
which was performed by heel ultrasound as opposed to dual X-ray absorptiometry (DXA) which is
considered the gold standard [50]. Although quantitative heel ultrasound performs well against DXA
in predicting fracture risk [51,52], it generally underestimates bone mineral density when compared
with DXA, with lower sensitivity (21–45%) but high specificity (87–96%) at a cut-off of −2.5 for an
equivalent DXA score [52]. This reflects our relatively low prevalence figures when compared to other
local prevalence studies that have reported osteoporosis in 3–12% of males and 8–43% of females over
age 50 [10,53].
5. Conclusions
At-risk coeliac serology, defined by the presence of an elevated anti-tTG antibody and a permissive
genotype, is highly prevalent in older Australian adults and is significantly associated with low bone
mineral density as measured by quantitative heel ultrasound. Few with at-risk serology were diagnosed
with CeD during long-term follow-up. The issue of false positive serology should be addressed in
studies where biopsy is used to confirm disease, as high anti-tTG levels are documented in autoimmune
and liver disease. We did not find a significant relationship between at-risk serology and fractures
during the follow-up period, as our analysis was underpowered for this outcome. The findings in
this study would support considering the diagnosis of osteoporosis in older patients with newly
diagnosed CeD.
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